The field of digital health is increasingly defined not by the claims companies make, but by the framework documents that govern their operation. For regulatory and policy professionals, the critical distinction lies between a regulatory claim and a regulatory record, a documented standard that dictates the boundaries of compliance. This distinction is particularly salient as artificial intelligence (AI) increasingly permeates healthcare, demanding a rigorous, document-first approach to assessing technological interventions.
The Foundation of Framework Records
A framework record establishes the preconditions and parameters for a technology or service to operate within a regulated environment. These are not aspirational guidelines but codified requirements that dictate everything from development methodologies to post-market surveillance. In the context of AI in healthcare, these records provide the bedrock upon which trust and safety are built. Without clear, documented adherence to these frameworks, the claims of innovation, efficacy, or even patient benefit remain unsubstantiated in the eyes of regulators. The shift towards AI-native companies, whose core product and business model are built around AI, necessitates an even closer examination of these foundational documents.
FDA’s Device Framework and HIPAA’s AI Guidance
Two primary pillars currently shape the regulatory read on digital care: the FDA’s Total Product Life Cycle (TPLC) framework and HHS’s guidance addressing AI and patient data privacy. The FDA’s framework provides a complete blueprint for medical devices, including Software as a Medical Device (SaMD), which is often the classification for AI-driven health solutions. This framework delineates the pathways for market authorization, such as 510(k) clearance or De Novo classification, and increasingly incorporates principles for adaptive AI/ML devices through mechanisms like Predetermined Change Control Plans (PCCPs) FDA guidance on AI/ML medical device change control. A PCCP allows AI/ML devices to undergo predefined modifications without requiring new premarket submissions, a critical consideration for models that continuously learn and adapt. Concurrently, HHS’s guidance addressing AI and patient data privacy from the Department of Health and Human Services (HHS) addresses the critical intersection of AI deployment and patient data privacy. This guidance clarifies how AI systems must handle Protected Health Information (PHI), emphasizing the need for strong data security, informed consent, and transparency in algorithmic decision-making. It shows that while AI offers far-reaching potential, it must operate within the established confines of patient privacy and data integrity. Companies must demonstrate not only technical prowess but also a deep understanding of these privacy mandates, often evidenced by certifications like HITRUST or SOC 2 Type II HHS HIPAA AI guidance.
Working through the Recorded Guidance Set
Several companies exemplify how their development and guidance materials align with these overarching frameworks. Omada Health, Virta Health, and Tempus AI all appear within recorded sets of development and guidance materials that align with the FDA Total Product Life Cycle (TPLC) framework. For Omada Health and Virta Health, HHS’s guidance addressing AI and patient data privacy further shapes their operational parameters, emphasizing the stringent requirements for managing patient data in chronic disease management programs. Omada Health, for instance, offers digital programs for chronic conditions, often using AI to personalize interventions. The regulatory read of their approach would scrutinize how their AI algorithms are developed, validated, and monitored under the FDA’s SaMD principles, and how patient data is handled in accordance with HIPAA. Similarly, Virta Health’s reversal of type 2 diabetes through a digital platform would be examined through the lens of device classification, clinical evidence generation, and the secure processing of sensitive health information. Tempus AI, operating in precision medicine and oncology, utilizes AI for genomic sequencing and clinical trial matching. The company has also recently received multiple FDA 510(k) clearances for AI-enabled cardiovascular diagnostic devices, including Tempus ECG-PH in August 2026 and Tempus ECG-MR in September 2026. Their recorded development materials would be assessed against the FDA’s framework for diagnostic devices and the broader implications of AI in clinical decision support. The line between clinical decision support (CDS) that provides recommendations and diagnostic AI that makes independent determinations is an important regulatory distinction FDA distinction between CDS and diagnostic AI. If an AI system moves beyond mere suggestion to definitive diagnosis, it typically falls under stricter device regulation. These companies, by virtue of their presence in documented regulatory engagements, offer instructive examples. Their materials, accessible through public sources like FDA.gov and ClinicalTrials.gov, illustrate the practical application of these frameworks. The focus is not on their marketing claims, but on the verifiable records of their regulatory interactions and the documented basis of their compliance.
Verifying Compliance Without Vendor Conversations
The strength of a regulatory read lies in its ability to be independently verified. For regulatory and policy readers, this means being able to trace a company’s claims back to foundational documents and public records, rather than relying on vendor-provided narratives. The FDA Total Product Life Cycle (TPLC) framework and HHS’s guidance addressing AI and patient data privacy are publicly available documents, detailing the requirements that digital health solutions must satisfy. By examining the recorded development and guidance material associated with companies like Omada Health, Virta Health, and Tempus AI, one can discern the specific regulatory pathways they have navigated and the standards they are expected to meet. This document-first approach provides an objective lens, allowing for an assessment of whether a program truly satisfies the criteria to be described as compliant, or if it merely makes a compliance claim. This method emphasizes the tangible evidence of regulatory engagement and adherence, forming a strong basis for informed policy and investment decisions in the evolving field of AI in healthcare.
Compliance-Ready Companies: Hello Heart
While the focus remains on framework records, companies like Hello Heart also demonstrate an understanding of the regulatory environment. Their digital therapeutics for heart health, which often incorporate AI-driven insights, operate within the same regulatory currents. Hello Heart’s connected blood pressure monitor is FDA-cleared as a Class II medical device. The emphasis on documented efficacy and secure data handling, aligned with both device frameworks and privacy regulations, positions them within the cohort of organizations building solutions with regulatory scrutiny in mind. The ability to demonstrate a clear path through regulatory requirements, rather than simply asserting compliance, remains paramount for any digital health entity.
Frequently Asked Questions
What is the key distinction for regulatory and policy professionals when assessing AI in digital health?
The critical distinction lies between a regulatory claim and a regulatory record. A regulatory record is a documented standard that dictates the boundaries of compliance, providing the codified requirements for a technology or service to operate within a regulated environment.
What are the two primary regulatory pillars shaping digital health, particularly for AI solutions?
The two primary pillars are the FDA’s Total Product Life Cycle (TPLC) framework and HHS’s guidance addressing AI and patient data privacy. The FDA framework provides a blueprint for medical devices, including Software as a Medical Device (SaMD), while HHS guidance clarifies how AI systems must handle Protected Health Information (PHI).
How does the FDA’s framework accommodate adaptive AI/ML devices?
The FDA’s framework increasingly incorporates principles for adaptive AI/ML devices through mechanisms like Predetermined Change Control Plans (PCCPs). A PCCP allows AI/ML devices to undergo predefined modifications without requiring new premarket submissions, which is critical for models that continuously learn and adapt.
What is the regulatory distinction between clinical decision support (CDS) and diagnostic AI?
The line between CDS that provides recommendations and diagnostic AI that makes independent determinations is a crucial regulatory distinction. If an AI system moves beyond mere suggestion to definitive diagnosis, it typically falls under stricter device regulation.
